AlloVir


AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Industries

Employees

51-200

Links


Org chart

Ann Leen
Chief Scientific Officer
Collapse
Julie
Vp, Biometrics
Francesca Cardarelli
Senior Medical Director Clinical Development
Vikas Sinha
President and Chief Financial Officer
Heather Amar
Executive Director, R&d Counsel
Sivaji Gundala
Head Of Quality Control

Board & advisors



Offices